Table 1.
Characteristics of the 251 new cases of malignancy (ANRS CO3 Aquitaine Cohort, 1998–2006)
| Type of malignancy | All (n = 251) | |||
|---|---|---|---|---|
| Non-AIDS-defining (n = 144) | AIDS-defining (n = 107) | |||
| n | n | |||
| Non-Hodgkin’s lymphoma | - | 61 | ||
| Kaposi’s sarcoma | - | 39 | ||
| Cervix carcinoma | - | 7 | ||
| Bronchopulmonary | 30 | - | ||
| Skin malignancy (melanoma) | 20 (4) | - | ||
| Hodgkin’s disease | 18 | - | ||
| Hepatocarcinoma | 16 | - | ||
| Anal malignancy | 14 | - | ||
| Other hemopathies | 6 | - | ||
| Other solid tumors | 40 | - | ||
| Characteristics (continuous variables) | Median | IQR | Median | IQR |
| Age at malignancy diagnosis (years) | 46.7 | 41.3–54.9 | 41.3 | 35.4–47.5 |
| Duration of follow-up in the study period (years) | 4.2 | 1.9–6.2 | 3.1 | 1.2–4.9 |
| Time since first HIV positive test (years) | 12.5 | 8.4–15.9 | 10.0 | 4.4–14.1 |
| Nadir of plasma HIV RNA viral load during the study period (Log copies/ml) | 1.7 | 1.7–2.7 | 3.0 | 1.8–4.0 |
| Plasma HIV RNA viral load value at the time of malignancy diagnosis (Log copies/ml) | 2.7 | 1.7–3.8 | 4.5 | 2.7–5.2 |
| Duration of follow-up with plasma HIV RNA viral load ≤ 500 copies/ml (years) | 1.5 | 0.3–3.5 | 0.0 | 0.0–0.7 |
| Nadir of CD4+ cell count during the study period (cells/mm3) | 186 | 93–296 | 129 | 21–281 |
| CD4+ cell count value at the time of malignancy diagnosis (cells/mm3) | 341 | 178–488 | 198 | 52–390 |
| Duration of cART use during the study period (years) | 2.9 | 0.7–5.3 | 1.6 | 0.5–3.5 |
| Characteristics (categorical variables) | % | % | ||
| Gender (men) | 83 | 78 | ||
| Intra venous drug users | 25 | 25 | ||
NOTE. IQR, Inter Quartile Range